Icon introduces new drug safety reporting solution

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/spainter_vfx)
(Image: Getty/spainter_vfx)

Related tags: Icon, Safety, Regulation, CRO, Pharmacovigilance

Icon’s new drug safety reporting platform automates complex processes to ensure compliance in the ‘ever-changing’ regulatory environment, says VP.

Launched at DIA Europe last week, the solution was received positively, said Quintin Van Wyk, VP of pharmacovigilance and safety reporting at Icon.

“Sponsors are especially interested in the capability to integrate with other clinical trial applications for increased efficiency and the opportunity decrease complexity in the process,”​ he told us.

Wyk said the new cloud-based solution features automated and configurable business rules to distribute “expedited and periodic submissions to all stakeholders,”​ including investigator sites, ethics committees, institutional review boards, and competent authorities.

The system verifies and translates pharmacovigilance regulatory requirements for 80 countries into date-stamped reporting rules to track changing requirements. It also is integrated with Icon’s electronic trial master file (eTMF) for automated filing and provides an auditable distribution trail, among other features that aim to reduce time and effort for study personnel, said Wyk.

“Drug safety reporting is complex due to the evolving, ever-changing regulatory environment,”​ he explained. “Running a clinical study across multiple countries requires careful consideration of global and national country legal pharmacovigilance requirements.”

Wyk noted that it is crucial to stay current with the latest developments, adapting reporting to the required format and deadlines. 

“One country or region may have numerous regulations, directives, laws, guidance and these rules may have overlapping or contradictory requirements,” ​he added. “Appropriate interpretation of pharmacovigilance regulations requires in-depth knowledge of both global and local regulations to decipher the reporting rules and avoid over or under reporting that might affect patient safety.”

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars